A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

231

Participants

Timeline

Start Date

September 27, 2012

Primary Completion Date

March 8, 2017

Study Completion Date

February 7, 2019

Conditions
Follicular LymphomaDiffuse Large B-Cell Lymphoma
Interventions
DRUG

Obinutuzumab

Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles.

DRUG

Pinatuzumab Vedotin

Pinatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.

DRUG

Polatuzumab Vedotin

Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.

DRUG

Rituximab

RTX 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle.

Trial Locations (41)

10016

New York University Cancer Cen, New York

10126

Azienda Ospedale San Giovanni, Turin

14263

Roswell Park Cancer Inst., Buffalo

20007

Georgetown University Medical Center Lombardi Cancer Center, Washington D.C.

20133

Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milan

22031

Fairfax N Virginia Hem/Onc PC, Fairfax

24014

Oncology & Hematolgy Associates of SW Va Inc. - Roanoke, Roanoke

33905

Florida Cancer Specialists - Fort Myers (Colonial Center Dr), Fort Myers

34232

Florida Cancer Specialists; Sarasota, Sarasota

34295

CHU Montpellier - Saint ELOI, Montpellier

37203

Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville

40138

A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna, Bologna

45242

Oncology Hematology Care Inc, Cincinnati

48109

Univ of Michigan Med School; Hematology Oncology, Ann Arbor

53705

Univ of Wisconsin-Madison, Madison

55131

Universitätsmedizin Johannes Gutenberg Universität; Klinik u. Poliklinik f. Neurologie, Mainz

59037

Hopital Claude Huriez - CHU Lille, Lille

69120

Uniklinik Heidelberg, Medizinische Klinik & Poliklinik V, Heidelberg

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

75246

Texas Oncology-Baylor Sammons Cancer Center, Dallas

75475

Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset), Paris

75702

Texas Oncology, P.A. - Tyler; Tyler Cancer Center, Tyler

76038

Centre Henri Becquerel; Hematologie, Rouen

78217

Cancer Care Centers of South Texas, San Antonio

78229

Texas Transplant Inst., San Antonio

80218

Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver

81377

Klinikum d.Universität München Campus Großhadern, München

89169

Comprehensive Cancer Centers of Nevada - Eastern Avenue, Las Vegas

90048

Cedars-Sinai Medical Center, Los Angeles

97239

Oregon Health Sciences Uni, Portland

98109

Fred Hutchinson Cancer Research Center, Seattle

98684

Northwest Cancer Specialists - Vancouver, Vancouver

98902

Yakima Valley Memorial Hospital/North Star Lodge, Yakima

94305-5820

Stanford Cancer Center, Stanford

07960

Hematology Oncology Associates; Carol G. Simon Ctr, Morristown

07962

Regional Cancer Care Associates LLC - Morristown, Morristown

97401-8122

Willamette Valley Cancer Ctr - 520 Country Club, Eugene

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 1H6

British Columbia Cancer Agency, Vancouver

H3T 1E2

McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal

1105 AZ

Academisch Medisch Centrum; Hematologie, Amsterdam

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY